Evidence map›Paper›PMID 38484752›Full record

ArticleLancet (London, England)2024

Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.

Marianne Shawe-Taylor, David Greenwood, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Crick COVID Serology Pipeline Investigators, Legacy Investigators and 11 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Cu(I)-N-Heterocyclic carbenes as potent inhibitors of SARS-CoV-2 replication.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Marianne Shawe-TaylorThe Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
David GreenwoodThe Francis Crick Institute, London NW1 1AT, UK.
Agnieszka HobbsCOVID Surveillance Unit, London NW1 1AT, UK.
Giulia DowgierCOVID Surveillance Unit, London NW1 1AT, UK.
Rebecca PennThe Francis Crick Institute, London NW1 1AT, UK.
Theo SandersonThe Francis Crick Institute, London NW1 1AT, UK.
Phoebe Stevenson-LeggettCOVID Surveillance Unit, London NW1 1AT, UK.
James BazireCOVID Surveillance Unit, London NW1 1AT, UK.
Ruth HarveyWorldwide Influenza Centre, London NW1 1AT, UK.
Crick COVID Serology Pipeline Investigators, Legacy Investigators
Vincenzo LibriNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
George KassiotisThe Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
Steve GamblinThe Francis Crick Institute, London NW1 1AT, UK.
Nicola S LewisWorldwide Influenza Centre, London NW1 1AT, UK.
Bryan WilliamsNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
Charles SwantonThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Sonia GandhiThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Edward J CarrThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Mary Y WuThe Francis Crick Institute, London NW1 1AT, UK.
David L V BauerThe Francis Crick Institute, London NW1 1AT, UK; Genotype-to-Phenotype 2 Consortium (G2P2-UK), UK.
Emma C WallThe Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK. Electronic address: emma.wall@crick.ac.uk.

Funding

Medical Research Council CC1283Medical Research Council CC2041Medical Research Council CC2060Medical Research Council MR/X006751/1Wellcome Trust CC1114Wellcome Trust CC2166
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19VaccinesHumansUnited KingdomVaccinationVaccines

Identifiers

PMID38484752
PMCPMC7616823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.